Want to see IN:ANUHPHR full AI Analyst Report?
ANUHPHR Stock Chart & Stats
₹77.53
-₹3.95(-1.77%)
At close: 4:00 PM EST
₹77.53
-₹3.95(-1.77%)
Day’s Range― - ―
52-Week Range₹66.72 - ₹115.00
Previous CloseN/A
Volume12.53K
Average Volume (3M)6.00K
Market Cap
₹8.17B
Enterprise Value₹7.91B
Total Cash (Recent Filing)₹135.33M
Total Debt (Recent Filing)₹2.27M
Price to Earnings (P/E)19.9
Beta0.72
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.92%
Share Statistics
EPS (TTM)2.00
Shares Outstanding100,224,000
10 Day Avg. Volume6,374
30 Day Avg. Volume5,996
Financial Highlights & Ratios
PEG Ratio-1.25
Price to Book (P/B)1.91
Price to Sales (P/S)0.87
P/FCF Ratio-61.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Exceptionally Conservative Balance SheetNear-zero debt gives the company durable financial flexibility to absorb shocks, fund working-capital swings or opportunistic capex without reliance on markets. Over 2–6 months this supports resilience versus peers during industry cycles and preserves capacity to invest in growth or deleverage.
Sustained Top-line Growth TrajectoryConsistent and accelerating revenue growth indicates expanding market access or higher volumes for API products. Durable top-line expansion supports scale economics, potential to absorb fixed costs, and provides a platform to rebuild margins if cost or mix issues are addressed.
Stable API Business Serving Domestic And Export MarketsA business model focused on API supply with domestic and export channels and recurring customer relationships yields predictable baseline demand. Structural pharmaceutical demand and repeat procurement cycles underpin durable revenue streams and reduce single-market dependence over medium term.
Bears Say
Sharp Weakening In Cash GenerationNegative operating and free cash flow despite prior positive cash conversion indicates working-capital stress or investment drag. Over the coming months this can constrain internal funding for inventories, capex, or supplier payments and force external financing despite low structural leverage.
Meaningful Margin CompressionA substantial fall in gross and net margins signals sustained input-cost pressures, pricing erosion, or adverse product mix. If structural, compressed margins reduce free cash, limit reinvestment and capital returns, and make long-term earnings growth harder absent clear margin recovery.
Earnings Decline And Easing Returns On EquityFalling ROE and negative EPS growth point to weakening profitability and capital efficiency. Over a multi-month horizon this may reflect sustained competitive or cost dynamics that impair the company’s ability to generate attractive returns on invested capital without operational or pricing improvements.
Anuh Pharma Limited News
ANUHPHR FAQ
What was Anuh Pharma Limited’s price range in the past 12 months?
Anuh Pharma Limited lowest stock price was ₹66.72 and its highest was ₹115.00 in the past 12 months.
What is Anuh Pharma Limited’s market cap?
Anuh Pharma Limited’s market cap is ₹8.17B.
When is Anuh Pharma Limited’s upcoming earnings report date?
Anuh Pharma Limited’s upcoming earnings report date is Aug 07, 2026 which is in 35 days.
How were Anuh Pharma Limited’s earnings last quarter?
Anuh Pharma Limited released its earnings results on May 20, 2026. The company reported ₹1.17 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.17.
Is Anuh Pharma Limited overvalued?
According to Wall Street analysts Anuh Pharma Limited’s price is currently Overvalued.
Does Anuh Pharma Limited pay dividends?
Anuh Pharma Limited pays a Annually dividend of ₹1.5 which represents an annual dividend yield of 1.92%. See more information on Anuh Pharma Limited dividends here
What is Anuh Pharma Limited’s EPS estimate?
Anuh Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anuh Pharma Limited have?
Anuh Pharma Limited has 100,224,000 shares outstanding.
What happened to Anuh Pharma Limited’s price movement after its last earnings report?
Anuh Pharma Limited reported an EPS of ₹1.17 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.375%.
Which hedge fund is a major shareholder of Anuh Pharma Limited?
Currently, no hedge funds are holding shares in IN:ANUHPHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Anuh Pharma Limited
Anuh Pharma Ltd. is an Indian enterprise specializing in the manufacturing and distribution of bulk drugs and various chemical compounds. The company provides a comprehensive selection of active pharmaceutical ingredients (APIs), encompassing macrolides, anti-tuberculosis agents, antibacterials, anti-asthmatics, anti-diabetic compounds, intermediates, expectorants, quinolones, anti-malarials, anti-gout medications, antibiotics, anti-platelet drugs, and antihistamines. Additionally, it produces corticosteroids valued for their anti-inflammatory, immunosuppressant, anti-pruritic, and anti-mitotic actions. Anuh Pharma is also engaged in developing new products within therapeutic categories such as coagulants, gastrointestinal treatments, anticonvulsants, and cholesterol-reducing medications. Its products are sold both domestically and to international markets. The company, established in 1960, maintains its headquarters in Mumbai, India.
Technical Analysis
Albert David Ltd
―
Kilitch Drugs (India) Limited
―
Sigachi Industries Limited
―
Wanbury Limited
―
Zim Laboratories Ltd.
―